| Administration route |
None |
| Dosage |
150E6 cells, 450E6 cells, 800E6 cells, 1200E6 cells |
| Pts |
4 |
| Age |
Adult, Older_Adult |
| Outcome |
58%(CR); 32%(PR); 90%(ORR) |
| Adverse reactions |
Common Hematological Toxicities: Grade 3-4 toxicities included anemia(62%), thrombocytopenia(54%), neutropenia(98%), and lymphopenia(100%). Cytokine Release Syndrome(CRS): Occurred in 96% of patients(48/50). Grade 1/2 CRS in 82% of patients, and Grade 3 CRS in 14% of patients. Tocilizumab was used in 40 patients(median 1 dose, range 1-4) and corticosteroids in 8 patients. Neurotoxicity(ICANS): Two cases observed, both grade 1 and 2. Hemophagocytic Lymphohistiocytosis(HLH): Developed in 2 patients. Safety: No irreversible organ toxicities or treatment-related deaths were reported. |
| References |
DOI:
10.1182/blood-2023-185069
|
|